NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial.
Source: MedWire News - Category: Consumer Health News Tags: Non-small-cell lung cancer Source Type: news